Is Binimetinib on the market?

On June 27, 2018, the U.S. Food and Drug Administration (FDA) approved the combination of bimetinib (Binimetinib) and encorafenib (canafenib) for use with an FDA-approved test to detect people with BRAF Patients with unresectable or metastatic melanoma and non-small cell lung cancer with V600E or V600K mutations, a non-competitive, selective small molecule inhibitor of mitogen-activated protein kinase (MEK1/2), bimetinib and canafenib from Array BioPharma Inc developed and sold under the trade names MEKTOVI and BRAFTOVI.xa0

Up to50% of patients with metastatic melanoma have mutations in BRAF, with V600 mutations being the most common. Bimetinib plus canafenib could help extend the survival of these patients without worsening their disease. Bimetinib's side effects are similar to other drugs in its class and are considered manageable. Therefore, the European Medicines Agency decided that the benefits of bimetinib outweighed its risks and it could be authorized for use in the EU. It was approved for marketing in September 2018.

The original drug bimetinib has not yet been launched in China, and therefore is not covered by medical insurance. Bimetiniboriginal drug sold overseas, specifications15mg*84 tablets may cost more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic drug of Bimetinib produced and launched. For more drug information and specific prices, please consult a medical consultant.